Changes to the 340B Program in 2026 – Inflation Reduction Act and More | Webinar

The federal 340B drug discount program has undergone substantial changes in recent years, with new challenges brought on by manufacturer restrictions and diminishing reimbursement counterbalanced by new opportunities. Perhaps one of the most significant changes are effective on January 1, 2026, when Inflation Reduction Act-mandated negotiated Medicare prices took effect for ten drugs.

This session provides an update on the latest changes to the 340B program, including early experiences with Inflation Reduction Act implementation.

Learning Objectives:

1. Understand how Medicare-negotiated pricing will impact 340B program operations and reimbursement
2. Navigate changes to 340B program compliance
3. Prepare your organization for the likely evolution of the 340B program.

Audience:

• Pharmacy Managers
• COOs
• CEOs
• CFOs
• Compliance Officers
• Executive Leadership

Presenter:

• Jason Reddish